Pillsbury advised leading medical genetics company Invitae in the sale of Research Use Only (RUO) kitted solutions by Integrated DNA Technologies, Inc., or IDT.

The transaction valued approximately $48 million, including total cash consideration. Particular licensed rights to Invitae’s Anchored Multiplex PCR (AMP™) technology were also included in the transaction along with a supply agreement with IDT to support Invitae’s personalized cancer monitoring services.

The Pillsbury deal team included Corporate partners Richard Blaylock and Mike Hird and senior associate Hana Cho, Real Estate partner Eric Kremer, Finance partner Alicia McKnight and associate Olivia Lugar, Emerging Growth & Venture Capital senior associate Walter Scott and senior legal analyst Rory O’Neil.

Click here to read the full press release.